#United States #New York #Class Action #Inc. #Rosen Law Firm #Disc Medicine

Rosen Law Firm Investigates Disc Medicine, Inc. Potential Class Action for Shareholder Losses

Rosen Law Firm Investigates Disc Medicine for Investor Losses

On September 16, 2026, the Rosen Law Firm, a prominent global law firm focused on investor rights, announced its ongoing investigation concerning Disc Medicine, Inc. (NASDAQ: IRON). The firm is examining potential securities claims on behalf of shareholders who may have suffered losses exceeding $100,000 due to alleged misleading business practices by Disc Medicine.

Background on the Investigation

The impetus for this investigation stems from a Complete Response Letter (CRL) issued by the U.S. Food and Drug Administration (FDA) on February 13, 2026. The CRL noted significant uncertainties surrounding Disc Medicine's New Drug Application (NDA) for the drug candidate bitopertin, leading to the FDA's refusal to approve the application. This critical regulatory setback caused Disc Medicine's stock to plummet by 22% on the very day the FDA announcement was made, leading to substantial financial losses for investors.

Rosen's investigation aims to determine whether Disc Medicine provided its shareholders with materially misleading information that could have influenced their investment decisions. Shareholders who purchased the company's securities during the relevant period may be entitled to compensation, potentially without any out-of-pocket expenses, due to the firm's contingency fee arrangement.

How to Get Involved

Affected shareholders of Disc Medicine are encouraged to participate in a class action against the firm for recovery of their losses. Interested investors can visit rosenlegal.com to submit a form or contact Phillip Kim, Esq. at 866-767-3653 for further information regarding the class action.

Rosen Law Firm emphasizes the importance of selecting qualified legal counsel, highlighting its impressive track record in securities class actions. The firm has secured large settlements on behalf of investors in the past, making it an appealing option for affected shareholders seeking justice and recovery.

Why Choose Rosen Law Firm?

The Rosen Law Firm's reputation and extensive experience make it a trusted advocate for investors. In 2019, the firm recovered over $438 million for its clients and has consistently ranked among the top firms for securities class action settlements. Additionally, its founding partner, Laurence Rosen, was acknowledged as a Titan of the Plaintiffs' Bar by Law360, underscoring the firm's reliability and success in this niche of legal practice.

With a history of notable recoveries and a commitment to diligent representation, Rosen Law Firm offers investors hope in navigating their potential claims against Disc Medicine, Inc. The firm possesses the resources and expertise necessary for successful litigation in the intricate world of securities laws and shareholder rights.

Conclusion

Investors who have incurred losses from investing in Disc Medicine, Inc. are strongly urged to take action. Participating in this class action could be a vital step toward recovering those losses. Shareholders can gain further insights and updates by following Rosen Law Firm's activities on their LinkedIn and Twitter accounts.

For more information, comments, or concerns, potential clients can reach out to the firm via email at [email protected].

Investors should stay informed about their legal rights and the ongoing developments concerning Disc Medicine, Inc. and should not hesitate to consult with expert legal counsel in this matter.